Arcus Biosciences (RCUS) Share-based Compensation (2017 - 2026)

Arcus Biosciences' Share-based Compensation history runs 10 years deep, the most recent figure standing at $19.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 18.75% year-over-year to $19.0 million; the TTM figure through Mar 2026 stood at $63.0 million (up 2000.0% YoY), while the FY2025 annual figure was $60.0 million, up 757.14% from the prior year.
• Share-based Compensation for Q1 2026 stood at $19.0 million, up from $15.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $20.0 million in Q1 2024, with the low at -$37.0 million in Q3 2023.
• The 5-year median for Share-based Compensation is $15.5 million (2022), against an average of $9.5 million.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 327.55% in 2023, then jumped 1300.0% in 2025.
• Arcus Biosciences' Share-based Compensation stood at $17.0 million in 2022, then sank by 317.65% to -$37.0 million in 2023, then jumped by 113.51% to $5.0 million in 2024, then surged by 200.0% to $15.0 million in 2025, then increased by 26.67% to $19.0 million in 2026.
• Business Quant data shows RCUS's Share-based Compensation at $19.0 million in Q1 2026, $15.0 million in Q4 2025, and $14.0 million in Q3 2025.